Novel ginsenoside monomer RT4 promotes colitis repair in mice by regulating miR‐144‐3p/SLC7A11 signaling pathway
Fundamental & Clinical Pharmacology · 2023-12 · 37 (6) · 1129-1138
DOI: 10.1111/fcp.12934 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 23.06.2023. Verfasst von Yao Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Ginsenosides, Colitis, MicroRNAs. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Wellcome Trust, Natural Science Foundation of Anhui Province.
Abstract (Originalsprache)
Background
Ginsenoside RT4 (RT4) is a new biologically active compound extracted from ginseng that possesses numerous medicinal and pharmacological properties. However, its potential therapeutic effect of ginsenoside RT4 on ulcerative colitis remains unknown. Methods and results In this study, we investigated the anti‐inflammatory effects of ginsenoside RT4 and its underlying molecular mechanism in the treatment of ulcerative colitis mice induced with dextran sulfate sodium (DSS). Our results demonstrate that ginsenoside RT4 effectively reduced weight, shortening of colonic tract length, colonic bowel damage, and disease activity index (DAI) scores in DSS‐induced colitis mice. Additionally, ginsenoside RT4 regulates miR‐144‐3p expression in DSS‐induced colitis mice, and we further confirmed that the solute carrier family 7 member 11 (SLC7A11) was the target gene of miR‐144‐3p by database analysis. Finally, ginsenoside RT4 inhibits the activation of the miR‐144‐3p/SLC7A11 signaling pathway, which alleviates colitis. Ginsenoside RT4 significantly decreased the expression of pro‐inflammatory cytokines TNF‐α and IL‐1β and increased the anti‐inflammatory cytokine IL‐10.
Conclusions
These findings suggest that ginsenoside RT4 may have therapeutic potential for treating ulcerative colitis by downregulating levels of miR‐144‐3p/SLC7A11 signaling pathway, which are expected to be useful in treating clinical ulcerative colitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.
- Anhui Province Key Laboratory of Immunology in Chronic Diseases, School of Laboratory Medicine, Bengbu Medical College, Bengbu, China.
- Department of Pharmaceutical Chemistry, School of Pharmacy, Jilin University of Medicine, Jilin, China.
- Department of Internal Medicine, Shanghai Xuhui District Central Hospital & Zhongshan-Xuhui Hospital, Shanghai, China.
- Department of Cardiology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
- Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry of Education of China, Xi'an, China.
ORCID-Profile: Yao Li
Förderung
- Wellcome Trust
- Natural Science Foundation of Anhui Province
Zitieren
APA
Li, Y., Han, L., Hou, B., & Ji, Y. (2023). Novel ginsenoside monomer RT4 promotes colitis repair in mice by regulating miR‐144‐3p/SLC7A11 signaling pathway. Fundamental & Clinical Pharmacology, 37(6), 1129-1138. https://doi.org/10.1111/fcp.12934
Vancouver
Li Y, Han L, Hou B, Ji Y. Novel ginsenoside monomer RT4 promotes colitis repair in mice by regulating miR‐144‐3p/SLC7A11 signaling pathway. Fundamental & Clinical Pharmacology. 2023;37(6):1129-1138. doi:10.1111/fcp.12934
BibTeX
@article{Li2023,
author = {Li, Yao and Han, Liu and Hou, Binfen and Ji, Yanhong},
title = {Novel ginsenoside monomer RT4 promotes colitis repair in mice by regulating miR‐144‐3p/SLC7A11 signaling pathway},
journal = {Fundamental & Clinical Pharmacology},
year = {2023},
volume = {37},
number = {6},
pages = {1129--1138},
doi = {10.1111/fcp.12934}
}
EUVIMED